Beacon Investment Advisory Services Inc. Has $16.94 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Beacon Investment Advisory Services Inc. has reduced its stake in Johnson & Johnson by 9.2%, owning 110,884 shares worth approximately $16.94 million after selling 11,193 shares in the second quarter.
• Johnson & Johnson recently reported quarterly earnings of $2.77 per share, surpassing analysts' expectations, and generated revenue of $23.74 billion, up 5.8% from the previous year.
• The company announced a quarterly dividend of $1.30 per share, reflecting an annualized dividend yield of 2.9%, with a current payout ratio of 55.61%.

Beacon Investment Advisory Services Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 110,884 shares of the company's stock after selling 11,193 shares during the quarter. Beacon Investment Advisory Services Inc.'s holdings in Johnson & Johnson were worth $16,937,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Highline Wealth Partners LLC lifted its stake in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson in the 1st quarter valued at $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.6%

NYSE JNJ opened at $177.71 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $427.99 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 2.25 and a beta of 0.40. The company has a 50 day moving average of $174.09 and a 200-day moving average of $161.97. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. Bank of America lifted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, The Goldman Sachs Group increased their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $181.40.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.